Amgen Inc. (AMGN)

Last Closing Price: 216.93 (2023-05-26)

Company Description

Amgen Inc. is the leading biotech companies world wide, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health & nephrology and neuroscience markets. It developed two most successful drugs, Epogen & Neupogen. Amgen successfully launched two next-generation products, Aranesp & Neulasta and also a biosimilar drug, Prolia/Xgeva. The acquisition of Immunex Corp gave Amgen access to the multi-blockbuster drug, Enbrel. Other products are Repatha, Blincyto, Parsabiv, Evenity, Aimovig, Lumakras/Lumykras, Kanjinti, Mvasi & Amgevita biosimilars. Amgen also has a promising pipeline of cancer drugs. It has one of the strongest cash positions in the biotech sector, which could be used to acquire more pipeline assets that could fuel long-term growth. The erythropoiesis-stimulating agents and granulocyte colony-stimulating factor franchise comprise Epogen/Aranesp and Neupogen/Neulasta respectively. Biosimilar drugs are also a key part of Amgen's growth strategy.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) $26.32B
Net Income (Most Recent Fiscal Year) $6.55B
PE Ratio (Current Year Earnings Estimate) 11.97
PE Ratio (Trailing 12 Months) 12.45
PEG Ratio (Long Term Growth Estimate) 1.71
Price to Sales Ratio (Trailing 12 Months) 4.43
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 21.67
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) 8.91
Pre-Tax Margin (Trailing 12 Months) 34.80%
Net Margin (Trailing 12 Months) 30.23%
Return on Equity (Trailing 12 Months) 248.47%
Return on Assets (Trailing 12 Months) 13.54%
Current Ratio (Most Recent Fiscal Quarter) 3.14
Quick Ratio (Most Recent Fiscal Quarter) 2.79
Debt to Common Equity (Most Recent Fiscal Quarter) 11.36
Inventory Turnover (Trailing 12 Months) 1.36
Book Value per Share (Most Recent Fiscal Quarter) $6.86
Earnings per Share (Most Recent Fiscal Quarter) $3.98
Earnings per Share (Most Recent Fiscal Year) $17.69
Diluted Earnings per Share (Trailing 12 Months) $14.71
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers - General
Common Shares Outstanding 534.33M
Free Float 531.28M
Market Capitalization $115.91B
Average Volume (Last 20 Days) 2.19M
Beta (Past 60 Months) 0.64
Percentage Held By Insiders (Latest Annual Proxy Report) 0.57%
Percentage Held By Institutions (Latest 13F Reports) 75.53%
Annual Dividend (Based on Last Quarter) $8.52
Dividend Yield (Based on Last Quarter) 3.93%